VS-6063

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

defactinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
BACKGROUND Docetaxel, the standard chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
Merck , Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer Release
  • 2018
DARMSTADT, Germany & NEW YORK & BOSTON--(BUSINESS WIRE)--Merck, Pfizer and Verastem announced today that they have entered into… (More)
Is this relevant?
2018
2018
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of normal and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… (More)
Is this relevant?
2016
2016
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2016
2016
T-03 Exposure-Response Analyses to Assess Lack of QT Prolongation by VS-6063 in Healthy Subjects or in Patients with non-Hematologic Malignancies
Methods: In Study B0761001 (n=46), the safety, pharmacokinetics (PK) and pharmacodynamics of single and multiple-doses of VS-6063… (More)
Is this relevant?
2015
2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Objective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2014
2014
302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… (More)
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2014
2014
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.
 
Is this relevant?
2013
2013
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
BACKGROUND We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the… (More)
Is this relevant?